RU2013142647A - Производные втор-гидроксициклогексила в качестве ингибиторов hsl для лечения диабета - Google Patents
Производные втор-гидроксициклогексила в качестве ингибиторов hsl для лечения диабета Download PDFInfo
- Publication number
- RU2013142647A RU2013142647A RU2013142647/04A RU2013142647A RU2013142647A RU 2013142647 A RU2013142647 A RU 2013142647A RU 2013142647/04 A RU2013142647/04 A RU 2013142647/04A RU 2013142647 A RU2013142647 A RU 2013142647A RU 2013142647 A RU2013142647 A RU 2013142647A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- phenyl
- hydroxy
- decan
- azaspiro
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims 13
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 50
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract 11
- -1 methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethoxy, trifluoroethoxy Chemical group 0.000 claims abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 5
- 239000001257 hydrogen Substances 0.000 claims abstract 5
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims abstract 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 4
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 claims abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 19
- 230000002265 prevention Effects 0.000 claims 18
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 12
- 201000001320 Atherosclerosis Diseases 0.000 claims 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 8
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 8
- 230000004064 dysfunction Effects 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 230000002107 myocardial effect Effects 0.000 claims 8
- 235000020824 obesity Nutrition 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000001476 alcoholic effect Effects 0.000 claims 5
- 230000007850 degeneration Effects 0.000 claims 5
- 210000004185 liver Anatomy 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- PPWLUVUZMIXMJC-DZKIICNBSA-N (5s,7s,8s)-8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1[C@H](OCC(F)(F)F)[C@@H](O)CC[C@@]11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 PPWLUVUZMIXMJC-DZKIICNBSA-N 0.000 claims 2
- YZTKPBAXESIKIE-CUSZFKRNSA-N (5s,7s,8s)-8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-[(1r)-2,2,2-trifluoro-1-methoxyethyl]phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1=CC([C@@H](OC)C(F)(F)F)=CC=C1N1C(=O)[C@]2(C[C@@H]([C@@H](O)CC2)OCC(F)(F)F)CC1 YZTKPBAXESIKIE-CUSZFKRNSA-N 0.000 claims 2
- BGHKCNHEBSHENM-UHFFFAOYSA-N 8-hydroxy-7-propan-2-yl-2-[4-(2,2,2-trifluoroethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(C(C)C)CC11C(=O)N(C=2C=CC(OCC(F)(F)F)=CC=2)CC1 BGHKCNHEBSHENM-UHFFFAOYSA-N 0.000 claims 2
- NLHHYKJVMWXELZ-UHFFFAOYSA-N 8-hydroxy-7-propan-2-yl-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(C(C)C)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 NLHHYKJVMWXELZ-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- PPWLUVUZMIXMJC-IIAWOOMASA-N (5r,7r,8r)-8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1[C@@H](OCC(F)(F)F)[C@H](O)CC[C@]11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 PPWLUVUZMIXMJC-IIAWOOMASA-N 0.000 claims 1
- IJQQUSSCHHFEGJ-MPTYRVRUSA-N (5s,7s,8s)-8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-[(1r)-2,2,2-trifluoro-1-hydroxyethyl]phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1=CC([C@@H](O)C(F)(F)F)=CC=C1N1C(=O)[C@]2(C[C@@H]([C@@H](O)CC2)OCC(F)(F)F)CC1 IJQQUSSCHHFEGJ-MPTYRVRUSA-N 0.000 claims 1
- SYPRGLCEKGZXFH-YCSHWKNNSA-N (5s,7s,8s)-8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-[(1r)-2,2,2-trifluoro-1-phenylmethoxyethyl]phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1[C@H](OCC(F)(F)F)[C@@H](O)CC[C@@]11C(=O)N(C=2C=CC(=CC=2)[C@@H](OCC=2C=CC=CC=2)C(F)(F)F)CC1 SYPRGLCEKGZXFH-YCSHWKNNSA-N 0.000 claims 1
- UISKTUYIECGCNM-GNBUJSLZSA-N (5s,7s,8s)-8-hydroxy-7-propan-2-yloxy-2-[4-[(1r)-2,2,2-trifluoro-1-methoxyethyl]phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1=CC([C@@H](OC)C(F)(F)F)=CC=C1N1C(=O)[C@]2(C[C@@H]([C@@H](O)CC2)OC(C)C)CC1 UISKTUYIECGCNM-GNBUJSLZSA-N 0.000 claims 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 1
- DHPMSQPFKXIQSS-UHFFFAOYSA-N 7-ethoxy-8-hydroxy-2-[4-(2,2,2-trifluoroethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OCC)CC11C(=O)N(C=2C=CC(OCC(F)(F)F)=CC=2)CC1 DHPMSQPFKXIQSS-UHFFFAOYSA-N 0.000 claims 1
- JNJPMTLZSXBHIJ-UHFFFAOYSA-N 7-ethoxy-8-hydroxy-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OCC)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 JNJPMTLZSXBHIJ-UHFFFAOYSA-N 0.000 claims 1
- ZYNDZSWTZGGJGC-UHFFFAOYSA-N 8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-(2,2,2-trifluoroethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1C(OCC(F)(F)F)C(O)CCC11C(=O)N(C=2C=CC(OCC(F)(F)F)=CC=2)CC1 ZYNDZSWTZGGJGC-UHFFFAOYSA-N 0.000 claims 1
- PPWLUVUZMIXMJC-UHFFFAOYSA-N 8-hydroxy-7-(2,2,2-trifluoroethoxy)-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1C(OCC(F)(F)F)C(O)CCC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 PPWLUVUZMIXMJC-UHFFFAOYSA-N 0.000 claims 1
- SUYFLKVYVRWKMI-UHFFFAOYSA-N 8-hydroxy-7-methoxy-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OC)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 SUYFLKVYVRWKMI-UHFFFAOYSA-N 0.000 claims 1
- TWYXVYSMMUCKOW-UHFFFAOYSA-N 8-hydroxy-7-propan-2-yloxy-2-[4-(2,2,2-trifluoroethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OC(C)C)CC11C(=O)N(C=2C=CC(OCC(F)(F)F)=CC=2)CC1 TWYXVYSMMUCKOW-UHFFFAOYSA-N 0.000 claims 1
- HNTWSIJLQIMPBZ-UHFFFAOYSA-N 8-hydroxy-7-propan-2-yloxy-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OC(C)C)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 HNTWSIJLQIMPBZ-UHFFFAOYSA-N 0.000 claims 1
- PTGRKADUKRSWIA-UHFFFAOYSA-N 8-hydroxy-7-propoxy-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(OCCC)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 PTGRKADUKRSWIA-UHFFFAOYSA-N 0.000 claims 1
- QGVFVHFQCBELNT-UHFFFAOYSA-N 8-hydroxy-7-propyl-2-[4-(2,2,2-trifluoroethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(CCC)CC11C(=O)N(C=2C=CC(OCC(F)(F)F)=CC=2)CC1 QGVFVHFQCBELNT-UHFFFAOYSA-N 0.000 claims 1
- CRLYLLMVSJJPLT-UHFFFAOYSA-N 8-hydroxy-7-propyl-2-[4-(trifluoromethoxy)phenyl]-2-azaspiro[4.5]decan-1-one Chemical compound C1CC(O)C(CCC)CC11C(=O)N(C=2C=CC(OC(F)(F)F)=CC=2)CC1 CRLYLLMVSJJPLT-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000000019 Sterol Esterase Human genes 0.000 claims 1
- 108010055297 Sterol Esterase Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158386.0 | 2011-03-16 | ||
| EP11158386 | 2011-03-16 | ||
| PCT/EP2012/054307 WO2012123432A1 (en) | 2011-03-16 | 2012-03-13 | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013142647A true RU2013142647A (ru) | 2015-04-27 |
Family
ID=45812793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142647/04A RU2013142647A (ru) | 2011-03-16 | 2012-03-13 | Производные втор-гидроксициклогексила в качестве ингибиторов hsl для лечения диабета |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8722721B2 (https=) |
| EP (1) | EP2686299A1 (https=) |
| JP (1) | JP6117709B2 (https=) |
| KR (1) | KR20140022840A (https=) |
| CN (1) | CN103415506B (https=) |
| BR (1) | BR112013022416A2 (https=) |
| CA (1) | CA2830126A1 (https=) |
| MX (1) | MX339513B (https=) |
| RU (1) | RU2013142647A (https=) |
| WO (1) | WO2012123432A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| CN104788360B (zh) * | 2015-03-30 | 2017-07-25 | 曲阜师范大学 | 3‑砜基螺环三烯酮类化合物及其制备方法 |
| CN117551046B (zh) * | 2023-11-17 | 2025-10-28 | 广东药科大学附属第一医院 | 二氨基脲类hsl抑制剂、制备方法及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| EP1529528A1 (en) * | 2003-11-07 | 2005-05-11 | Universitätsklinikum Freiburg | 2-pyrrolidone derivatives and their use in protecting mammalian cells against oxidation stress |
| WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| ATE471311T1 (de) * | 2006-04-25 | 2010-07-15 | Lilly Co Eli | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 |
| US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| TW201118069A (en) * | 2009-10-28 | 2011-06-01 | Lundbeck & Co As H | Spirolactam derivatives and uses of same |
| US8389539B2 (en) * | 2009-12-01 | 2013-03-05 | Hoffman-La Roche Inc. | Azacyclic derivatives |
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| TW201206898A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
-
2012
- 2012-03-08 US US13/414,753 patent/US8722721B2/en not_active Expired - Fee Related
- 2012-03-13 JP JP2013558403A patent/JP6117709B2/ja active Active
- 2012-03-13 BR BR112013022416A patent/BR112013022416A2/pt not_active IP Right Cessation
- 2012-03-13 KR KR1020137027122A patent/KR20140022840A/ko not_active Ceased
- 2012-03-13 CN CN201280012084.XA patent/CN103415506B/zh not_active Expired - Fee Related
- 2012-03-13 WO PCT/EP2012/054307 patent/WO2012123432A1/en not_active Ceased
- 2012-03-13 EP EP12708036.4A patent/EP2686299A1/en not_active Withdrawn
- 2012-03-13 RU RU2013142647/04A patent/RU2013142647A/ru not_active Application Discontinuation
- 2012-03-13 CA CA2830126A patent/CA2830126A1/en not_active Abandoned
- 2012-03-13 MX MX2013010006A patent/MX339513B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX339513B (es) | 2016-05-30 |
| EP2686299A1 (en) | 2014-01-22 |
| KR20140022840A (ko) | 2014-02-25 |
| CN103415506A (zh) | 2013-11-27 |
| JP2014508178A (ja) | 2014-04-03 |
| CN103415506B (zh) | 2015-08-05 |
| MX2013010006A (es) | 2013-12-06 |
| BR112013022416A2 (pt) | 2016-12-13 |
| CA2830126A1 (en) | 2012-09-20 |
| US8722721B2 (en) | 2014-05-13 |
| WO2012123432A1 (en) | 2012-09-20 |
| JP6117709B2 (ja) | 2017-04-19 |
| HK1190706A1 (en) | 2014-07-11 |
| US20120238613A1 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2602813T3 (es) | Nuevos compuestos como moduladores de GPR-119 | |
| RU2572624C2 (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств | |
| RU2013142647A (ru) | Производные втор-гидроксициклогексила в качестве ингибиторов hsl для лечения диабета | |
| JP2012501312A5 (https=) | ||
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| RU2012146875A (ru) | Азациклические спиропроизводные в качестве ингибиторов hsl | |
| JP2009533410A5 (https=) | ||
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| EA200970655A1 (ru) | 6-замещенные пиримидины, ингибирующие вич | |
| NZ597247A (en) | Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme | |
| RU2010139806A (ru) | Новые производные пирроло[3,2-d]пиримидин-4-она и их применение в терапии | |
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| JP2013518129A5 (https=) | ||
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| NZ600367A (en) | 2-pyridone compounds | |
| JP2013500997A5 (https=) | ||
| KR20130130815A (ko) | Gpr119 수용체 작용제로서 이환형 헤테로아릴 화합물 | |
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| WO2013012485A3 (en) | Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| JP2013523814A5 (https=) | ||
| TW201924679A (zh) | 抗腫瘤劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20180522 |